Kaposi's sarcoma staging

Kaposi's sarcoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Kaposi's sarcoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Kaposi's sarcoma staging On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Kaposi's sarcoma staging All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Kaposi's sarcoma staging
CDC on Kaposi's sarcoma staging
Kaposi's sarcoma staging in the news
Blogs on Kaposi's sarcoma staging
Directions to Hospitals Treating Kaposi's sarcoma
Risk calculators and risk factors for Kaposi's sarcoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [3]

Overview

There is no established system for the staging of Kaposi's sarcoma among immune competent patients. However, the staging of AIDS-associated Kaposi's sarcoma is based on the AIDS Clinical Trials Group (ACTG) staging system. According to the ACTG staging system, there are 2 groups of AIDS-associated Kaposi's sarcoma based on the tumor size, patients immune status, and the presence of any systemic illness.

Staging

• There is no established system for the staging of Kaposi's sarcoma among immune competent patients.
• The staging of AIDS-associated Kaposi's sarcoma is based on the AIDS Clinical Trials Group (ACTG) staging system. According to the ACTG staging system, there are 2 groups of AIDS-associated Kaposi's sarcoma based on the tumor size, patients immune status, and the presence of any systemic illness.

Factors	Good Risk (Subscript 0)	Poor Risk (Subscript 1)
Tumor (T)	Confined to skin and lymph nodes Minimal oral lesions (non-nodular kaposi's sarcoma confined to the palate)	Tumor-associated edema or ulceration Extensive oral lesions present Gastrointestinal lesions present Kaposi sarcoma present in other non-nodal viscera
Immune system (I)	CD4 T cell count ≥ 150/mL	CD4 T cell count < 150/mL
Systemic illness (S)	No previous history of opportunistic infection or thrush B symptoms are not present Karnofsky performance status score ≥ 70	Positive history of opportunistic infections or oral thrush B symptoms are present Karnofsky performance status score < 70

• Early stage groups, which are associated with a good risk, include T0I0S0.
• Advanced stage groups, which are associated with a poor risk, include any combination of the TIS system that is not T0I0S0. For example, poor risk groups include T1I0S0, T1I1S0, T1I0S1, T1I1S0, T0I1S0, T1I1S1, etc. Thus, any poor risk feature in the TIS staging system places a patient into the poor risk category overall.

References

Template:WH Template:WS